Fumihiko Ishikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fumihiko Ishikawa has a total of 286 co-authors. Here are the top co-authors by number of shared publications:
- Anne K. Wouters
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
21 shared publications - Arnoud H. de Ru
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands
21 shared publications - Dennis F. G. Remst
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
21 shared publications - Dirk M. van der Steen
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
21 shared publications - J. H. Frederik Falkenburg
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
21 shared publications - Masashi Matsuda
Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
21 shared publications
Latest Publications
- 15 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (16) , 1998-2012
Immunoglobulin constant domains as targets for T-cell receptor–based treatment of multiple myeloma
Despite major progress with chimeric antigen receptor T-cell therapy, multiple myeloma (MM) remains largely incurable and most patients relapse. To broaden therapeutic options and overcome antigen escape, we explored T-cell receptor (TCR)–based targeting of intracellular antigens derived from immunoglobulin heavy chain constant domains. Using HLA class-I peptidomics, we identified 9 immunoglobulin G (IgG)– or IgA-derived peptides presented by common HLA alleles (HLA-A∗01:01, HLA-A∗02:01, HLA-A∗03:01, and HLA-B∗07:02). High-avidity T-cell clones recognizing 4 of these epitopes were isolated from HLA-mismatched healthy donors. The transfer of these immunoglobulin-specific TCRs into donor T cells conferred potent and selective recognition of IgG- or IgA-expressing MM cell lines, sparing antigen-negative cells. Safety profiling confirmed strict HLA-restricted specificity without cross-reactivity toward other HLA alleles, non–B-lineage tumor cell lines, or healthy tissues, except for the depletion of isotype-matched B cells. Immunoglobulin-TCR T cells efficiently lysed patient-derived MM cells ex vivo and eradicated established IgA- or IgG-expressing MM tumors in murine xenograft models. Mechanistic studies revealed that dendritic cells could cross-present immunoglobulin peptides at high serum concentrations, potentially enhancing T-cell activation in vivo. Importantly, subtype-specific depletion of B cells implies that immunoglobulin-TCR T-cell therapy could partly preserve humoral immunity, reducing the need for antibody replacement compared with pan–B-cell depletion strategies. Collectively, these findings establish immunoglobulin heavy chain constant domains as promising targets for TCR-based cellular immunotherapy in MM and potentially other immunoglobulin-producing malignancies or autoantibody-mediated autoimmune diseases.
- 15 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (16) , 1998-2012
Immunoglobulin constant domains as targets for T-cell receptor–based treatment of multiple myeloma
Despite major progress with chimeric antigen receptor T-cell therapy, multiple myeloma (MM) remains largely incurable and most patients relapse. To broaden therapeutic options and overcome antigen escape, we explored T-cell receptor (TCR)–based targeting of intracellular antigens derived from immunoglobulin heavy chain constant domains. Using HLA class-I peptidomics, we identified 9 immunoglobulin G (IgG)– or IgA-derived peptides presented by common HLA alleles (HLA-A∗01:01, HLA-A∗02:01, HLA-A∗03:01, and HLA-B∗07:02). High-avidity T-cell clones recognizing 4 of these epitopes were isolated from HLA-mismatched healthy donors. The transfer of these immunoglobulin-specific TCRs into donor T cells conferred potent and selective recognition of IgG- or IgA-expressing MM cell lines, sparing antigen-negative cells. Safety profiling confirmed strict HLA-restricted specificity without cross-reactivity toward other HLA alleles, non–B-lineage tumor cell lines, or healthy tissues, except for the depletion of isotype-matched B cells. Immunoglobulin-TCR T cells efficiently lysed patient-derived MM cells ex vivo and eradicated established IgA- or IgG-expressing MM tumors in murine xenograft models. Mechanistic studies revealed that dendritic cells could cross-present immunoglobulin peptides at high serum concentrations, potentially enhancing T-cell activation in vivo. Importantly, subtype-specific depletion of B cells implies that immunoglobulin-TCR T-cell therapy could partly preserve humoral immunity, reducing the need for antibody replacement compared with pan–B-cell depletion strategies. Collectively, these findings establish immunoglobulin heavy chain constant domains as promising targets for TCR-based cellular immunotherapy in MM and potentially other immunoglobulin-producing malignancies or autoantibody-mediated autoimmune diseases.
- Open Access
- 26 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Affinity- and epitope-dependent pathogenicity of GM-CSF autoantibodies in patients with autoimmune pulmonary alveolar proteinosis
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease caused by autoantibodies targeting granulocyte-macrophage colony-stimulating factor (GM-CSF). Although serum GM-CSF autoantibody levels are markedly increased in aPAP patients, total antibody titer does not correlate with disease severity. Here, we characterize 186 monoclonal anti-GM-CSF autoantibodies derived from GM-CSF-specific B cells in 28 aPAP patients with varying disease severity, including three longitudinal cohorts, to determine whether epitope specificity and affinity of the autoantibodies contribute to disease pathophysiology. We classify these antibodies into two groups based on their epitopes: class 1 (targeting A, BD, or D epitopes) and class 2 (targeting B or C epitopes). In class 1 antibodies, affinity strongly correlates with neutralization activity, whereas this relationship is weak or absent in class 2 antibodies. High-affinity class 1 antibodies are present at higher levels in patients with more severe disease and are sufficient to induce PAP symptoms in a humanized mouse model. Thus, these findings identify epitope specificity and affinity as key determinants of pathogenicity and provide a mechanistic framework for understanding why total serum autoantibody levels fail to reflect disease severity in aPAP.
- 26 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAffinity- and epitope-dependent pathogenicity of GM-CSF autoantibodies in patients with autoimmune pulmonary alveolar proteinosis
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease caused by autoantibodies targeting granulocyte-macrophage colony-stimulating factor (GM-CSF). Although serum GM-CSF autoantibody levels are markedly increased in aPAP patients, total antibody titer does not correlate with disease severity. Here, we characterize 186 monoclonal anti-GM-CSF autoantibodies derived from GM-CSF-specific B cells in 28 aPAP patients with varying disease severity, including three longitudinal cohorts, to determine whether epitope specificity and affinity of the autoantibodies contribute to disease pathophysiology. We classify these antibodies into two groups based on their epitopes: class 1 (targeting A, BD, or D epitopes) and class 2 (targeting B or C epitopes). In class 1 antibodies, affinity strongly correlates with neutralization activity, whereas this relationship is weak or absent in class 2 antibodies. High-affinity class 1 antibodies are present at higher levels in patients with more severe disease and are sufficient to induce PAP symptoms in a humanized mouse model. Thus, these findings identify epitope specificity and affinity as key determinants of pathogenicity and provide a mechanistic framework for understanding why total serum autoantibody levels fail to reflect disease severity in aPAP.
- Open Access
- 26 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 101
CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of B-cell malignancies, but its success in acute myeloid leukemia (AML) remains limited. Durable responses depend on the formation of long-lived memory T cells, whereas T cell exhaustion contributes to non-response and relapse. In patients with AML who achieved remission after cord blood transplantation, we here first observe enrichment of memory T cells with high expression of the chemokine receptor CXCR4. Next, we show that engineering CAR-T cells to co-express CXCR4 enhances their persistence and anti-leukemic activity in patient-derived xenograft models. Using single-cell profiling and metabolic analysis, we find that CXCR4 promotes memory-associated transcriptional programs, reduces exhaustion, and supports oxidative metabolism. These effects are observed with CAR-T cells targeting CD25 or CD96 as AML-associated targets. Our results indicate that CXCR4 strengthens CAR-T cell memory and durability, offering a strategy to improve immunotherapy outcomes in AML and beyond.
- 26 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 101
Open AccessCXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of B-cell malignancies, but its success in acute myeloid leukemia (AML) remains limited. Durable responses depend on the formation of long-lived memory T cells, whereas T cell exhaustion contributes to non-response and relapse. In patients with AML who achieved remission after cord blood transplantation, we here first observe enrichment of memory T cells with high expression of the chemokine receptor CXCR4. Next, we show that engineering CAR-T cells to co-express CXCR4 enhances their persistence and anti-leukemic activity in patient-derived xenograft models. Using single-cell profiling and metabolic analysis, we find that CXCR4 promotes memory-associated transcriptional programs, reduces exhaustion, and supports oxidative metabolism. These effects are observed with CAR-T cells targeting CD25 or CD96 as AML-associated targets. Our results indicate that CXCR4 strengthens CAR-T cell memory and durability, offering a strategy to improve immunotherapy outcomes in AML and beyond.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Supplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Supplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 8 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Boxplots depicting (A) CDH23 and (B) LOXHD1 expression in various tumor types (TCGA data n=30) and healthy tissue types (TCGA data n=30 and GTEx data n=5-20). Red, green and white boxplots represent tumor types (TCGA data), healthy tissues (TCGA data), and healthy tissues (GTEx), respectively. Boxplots extend from first to third quartile, the horizontal line represent the median expression value. The whiskers represent the minimum and maximum expression value (1.5 IQR from the first and third quartile). Outliers are defined as being 1.5*IQR or more above the third or below the first quartile, respectively. Y-axis abbreviations are described in supplemental table 1. (FC: fold change, GTEx: genotype-tissue expression, IQR: interquartile range, log2-CPM: log2-transformed counts per million, TCGA: The cancer genome atlas)
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 8 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Boxplots depicting (A) CDH23 and (B) LOXHD1 expression in various tumor types (TCGA data n=30) and healthy tissue types (TCGA data n=30 and GTEx data n=5-20). Red, green and white boxplots represent tumor types (TCGA data), healthy tissues (TCGA data), and healthy tissues (GTEx), respectively. Boxplots extend from first to third quartile, the horizontal line represent the median expression value. The whiskers represent the minimum and maximum expression value (1.5 IQR from the first and third quartile). Outliers are defined as being 1.5*IQR or more above the third or below the first quartile, respectively. Y-axis abbreviations are described in supplemental table 1. (FC: fold change, GTEx: genotype-tissue expression, IQR: interquartile range, log2-CPM: log2-transformed counts per million, TCGA: The cancer genome atlas)
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Supplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Supplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Peptide titrations of T-cell clones selected to recognize peptide-loaded and gene transduced Raji cells. IFN-ƴ production (ng/mL) of T-cell clones cocultured overnight with Raji cells (transduced with HLA-A2, B7 or B35) loaded with titrated peptide concentrations (E:T=1:6). Graphs are separated based on T-cell specificity. The five selected T-cell clones are shown in color. Values represent averaged duplicate values. (E:T: effector:target ratio)
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Peptide titrations of T-cell clones selected to recognize peptide-loaded and gene transduced Raji cells. IFN-ƴ production (ng/mL) of T-cell clones cocultured overnight with Raji cells (transduced with HLA-A2, B7 or B35) loaded with titrated peptide concentrations (E:T=1:6). Graphs are separated based on T-cell specificity. The five selected T-cell clones are shown in color. Values represent averaged duplicate values. (E:T: effector:target ratio)